Investigation of SP94 peptide as a specific probe for hepatocellular carcinoma imaging and therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Yanli ^a,b,c   Hu, Yan ^a,b   Xiao, Jie ^a,b   Liu, Guobing ^a,b   Li, Xiao ^a,b   Zhao, Yanzhao ^a,b   Tan, Hui ^a,b   Shi, Hongcheng ^a,b   Cheng, Dengfeng ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MEDICAL IMAGING   (China)

^c JINING NO 1 PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; TECHNETIUM;

ANIMAL; APOPTOSIS; DRUG SCREENING; ENDOCYTOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; NUDE MOUSE; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; LIVER NEOPLASMS; MALE; MICE, NUDE; PEPTIDES; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988835890     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33511     Document Type: Article

References (37)

1. Jemal, A., et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7, 448-458 (2010).
3. Ferlay, J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917 (2010).
4. Nguyen, V. T., Law, M. G. & Dore, G. J. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 16, 453-463 (2009).
5. Zhang, J. Y. Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun Rev 6, 143-148 (2007).
6. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24, 389-427 (2003).
7. Lo, A., Lin, C. T. & Wu, H. C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7, 579-589 (2008).
8. Toita, R., et al. A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells. Chem Commun (Camb) 49, 7442-7444 (2013).
9. Toita, R., et al. Development of human hepatocellular carcinoma cell-targeted protein cages. Bioconjug Chem 23, 1494-1501 (2012).
10. Ashley, C. E., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10, 389-397 (2011).
11. Ashley, C. E., et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 5, 5729-5745 (2011).
12. Guo, H., Gallazzi, F. & Miao, Y. Design and evaluation of new Tc-99m-labeled lactam bridge- cyclized alpha-MSH peptides for melanoma imaging. Mol Pharm 10, 1400-1408 (2013).
13. Maresca, K. P., et al. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide. Bioconjug Chem 21, 1032-1042 (2010).
14. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem Soc Rev 33, 445-461 (2004).
15. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 60, 1347-1370 (2008).
16. Luo, T. Y., et al. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol 36, 81-88 (2009).
17. Luo, T. Y., Lo, A. R., Hsieh, B. T. & Lin, W. J. A design for automatic preparation of highly concentrated 188Re-perrhenate solutions. Appl Radiat Isot 65, 21-25 (2007).
18. Ercan, M. T. & Caglar, M. Therapeutic radiopharmaceuticals. Curr Pharm Des 6, 1085-1121 (2000).
19. Jeong, J. M. & Chung, J. K. Therapy with 188Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 18, 707-717 (2003).
20. Meng, T.-T., Li, J. Q. & Qi, X. R. Preparation and evaluation of lipidmatrix nanocarrier codelivery gene and sensibilizer to elevate docetaxel antitumor. J Chin Pharm Sci 23, 145-152 (2014).
21. Teodoro, R., Faintuch, B. L., Nez, E. G. & Queiroz, R. G. Neurotensin (8-13) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol 38, 113-120 (2011).
22. Faintuch, B. L., et al. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 35, 401-411 (2008).
23. Biechlin, M. L., Bonmartin, A., Gilly, F. N., Fraysse, M. & du Moulinet d'Hardemare, A. Radiolabeling of annexin A5 with (99 m) Tc: comparison of HYNIC-Tc vs. iminothiolane-Tc- tricarbonyl conjugates. Nucl Med Biol 35, 679-687 (2008).
24. Decristoforo, C., et al. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol 33, 945-952 (2006).
25. Decristoforo, C. & Mather, S. J. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 26, 389-396 (1999).
26. Erfani, M., Zarrabi Ahrabi, N., Shafiei, M. & Shirmardi, S. P. A. (99 m) Tc-tricine-HYNIC- labeled peptide targeting the neurotensin receptor for single-photon imaging in malignant tumors. J Labelled Comp Radiopharm 57, 125-131 (2014).
27. Garcia Garayoa, E., et al. Chemical and biological characterization of new Re(CO)3/[99mTc] (CO)3 bombesin analogues. Nucl Med Biol 34, 17-28 (2007).
28. Luo, T. Y., et al. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann Nucl Med 29, 52-62 (2015).
29. Li, S., et al. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 26, 919-922 (2001).
30. Howell, R. C., et al. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug Chem 18, 1739-1748 (2007).
31. Ananias, H. J., et al. (99m) technetium-HYNIC(tricine/TPPTS)-Aca-bombesin (7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 8, 1165-1173 (2011).
32. Decristoforo, C., Melendez-Alafort, L., Sosabowski, J. K. & Mather, S. J. 99 mTc-HYNIC-[Tyr3]- octreotide for imaging somatostatinreceptor- positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41, 1114-1119 (2000).
33. Ji, S., Zhou, Y., Shao, G. & Liu, S. Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules. Bioconjug Chem 24, 701-711 (2013).
34. Liu, Y., et al. (99 m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol 41, 450-456 (2014).
35. Yang, Y., Ji, S. & Liu, S. Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides. Bioconjug Chem 25, 1720-1729 (2014).
36. Ocampo-Garcia, B. E., et al. Design and biological evaluation of 99mTc-N2S2-Tat(49-57)-c(RGDyK): a hybrid radio-pharmaceutical for tumors expressing a (v) β (3) integrins. Nucl Med Biol 40, 481-487 (2013).
37. Wang, H. Y., et al. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma. Int J Radiat Biol 89, 346-355 (2013).